GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

Search

First Advantage Corp

Atvērts

SektorsRūpniecība

15.75 -5.46

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

15.74

Max

16.79

Galvenie mērījumi

By Trading Economics

Ienākumi

59M

-41M

Pārdošana

47M

355M

P/E

Sektora vidējais

609.333

42.612

Peļņas marža

-11.617

Darbinieki

10,000

EBITDA

85M

69M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+19.91% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-28M

3.2B

Iepriekšējā atvēršanas cena

21.21

Iepriekšējā slēgšanas cena

15.75

Ziņu noskaņojums

By Acuity

50%

50%

209 / 461 Rangs Industrials

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

First Advantage Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. aug. 21:42 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025. g. 4. aug. 21:21 UTC

Peļņas
Galvenie tirgus virzītāji

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025. g. 4. aug. 20:45 UTC

Peļņas

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025. g. 4. aug. 19:15 UTC

Galvenie tirgus virzītāji

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025. g. 4. aug. 23:41 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. aug. 23:41 UTC

Tirgus saruna

Nikkei May Rise on Fed Stimulus Hopes

2025. g. 4. aug. 23:28 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 4. aug. 23:28 UTC

Tirgus saruna

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025. g. 4. aug. 21:30 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025. g. 4. aug. 21:21 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025. g. 4. aug. 21:18 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025. g. 4. aug. 20:25 UTC

Tirgus saruna

India Hits Back Over Russian Oil Purchases -- Market Talk

2025. g. 4. aug. 20:25 UTC

Peļņas

Transocean 2Q Loss $938M >RIG

2025. g. 4. aug. 20:25 UTC

Peļņas

Transocean 2Q Loss/Shr $1.06 >RIG

2025. g. 4. aug. 20:18 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025. g. 4. aug. 20:15 UTC

Peļņas

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025. g. 4. aug. 20:13 UTC

Peļņas

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025. g. 4. aug. 20:09 UTC

Peļņas

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025. g. 4. aug. 20:06 UTC

Peļņas

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025. g. 4. aug. 19:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025. g. 4. aug. 19:28 UTC

Tirgus saruna

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025. g. 4. aug. 19:07 UTC

Tirgus saruna

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025. g. 4. aug. 18:27 UTC

Tirgus saruna

Gold Climbs on Rate Cut Speculation -- Market Talk

Salīdzinājums

Cenas izmaiņa

First Advantage Corp Prognoze

Cenas mērķis

By TipRanks

19.91% augšup

Prognoze 12 mēnešiem

Vidējais 19.75 USD  19.91%

Augstākais 21 USD

Zemākais 18 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi First Advantage Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

3

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

14.98 / N/AAtbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

209 / 461 Rangs Rūpniecība

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par First Advantage Corp

First Advantage Corporation provides employment background screening, identity, and verification solutions worldwide. It offers pre-onboarding products and solutions, such as criminal background checks, drug/health screening, extended workforce screening, FBI channeling, identity checks and biometric fraud mitigation tools, education/work history verification, driver records and compliance, healthcare credentials, executive screening, and other screening products. The company also provides post-onboarding solutions, including criminal records monitoring, healthcare sanctions, motor vehicle records, social media screening, and global sanctions and licenses; and other products comprising fleet/vehicle compliance, hiring tax credits and incentives, resident/tenant screening, and investigative research. Its products and solutions are used by personnel in recruiting, human resources, risk, compliance, vendor management, safety, and/or security in global enterprises, mid-sized, and small companies. The company was formerly known as Fastball Intermediate, Inc. and changed its name to First Advantage Corporation in March 2021. First Advantage Corporation was founded in 2002 and is based in Atlanta, Georgia.